<DOC>
	<DOC>NCT02976116</DOC>
	<brief_summary>Fruquintinib in combination with Gefitinib as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring activating EGFR mutations : a single-arm, multicenter, phase II study</brief_summary>
	<brief_title>A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This phase II trial will evaluate the combination of fruquintinib and gefitinib in advanced NSCLC. The endpoint will be to evaluate the efficacy and safety of the combination.</detailed_description>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Signed Informed Consent Form. Age between 18 to 75 years old. Histologically or cytological documented stage IIIB/IV nonsquamous nonsmall cell lung cancer patients who have never received systematic treatment for the latestage disease. ECOG 01 Patients must have measurable lesions Prior systematic treatment for the advanced NSCLC Absolute neutrophil count (ANC) &lt; 1.5×109 /L, or platelet count &lt; 100 ×109/L, or hemoglobin &lt; 9 g/dL Total bilirubin &gt; 1 ULN; SGOT (AST), SGPT (ALT), &gt; 1.5 ULN; for patient with liver metastasis，AST or ALT &gt; 3 ULN Known HIV positive Hypersensitivity to either of the investigation drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Fruquintinib</keyword>
	<keyword>NSCLC</keyword>
	<keyword>1st line</keyword>
</DOC>